CLEARSIDE BIOMEDICAL INC
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 30
- Market Cap
- $75.4M
- Website
- http://www.clearsidebio.com
Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05891548
- Locations
- 🇺🇸
Retina Group of Florida, Fort Lauderdale, Florida, United States
🇺🇸Southeast Retina Center, Augusta, Georgia, United States
🇺🇸Western Carolina Retinal Associates P.A., Asheville, North Carolina, United States
Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05131646
- Locations
- 🇺🇸
Southeast Retina Center, Augusta, Georgia, United States
🇺🇸Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸Retina Consultants of Texas, The Woodlands, Texas, United States
Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04626128
- Locations
- 🇺🇸
Northern California Retina Vitreous Associates Medical Group, LLC, Mountain View, California, United States
🇺🇸Retinal Consultants Medical Group, Sacramento, California, United States
🇺🇸Retinal Consultants of Arizona, Phoenix, Arizona, United States
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
- Conditions
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT03203447
- Locations
- 🇺🇸
Win Retina, Arcadia, California, United States
🇺🇸Retina Vitreous Medical Group, Beverly Hills, California, United States
🇺🇸Macula and Retina Institute, Glendale, California, United States
Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT03126786
- Locations
- 🇺🇸
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸Texas Retina Associates-Arlington, Arlington, Texas, United States
🇺🇸Retina Centers, PC, Tucson, Arizona, United States
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03097315
- Locations
- 🇺🇸
Retinal Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View, California, United States
🇺🇸Retina Group of Florida, Fort Lauderdale, Florida, United States
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
- Conditions
- Interventions
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT02980874
- Locations
- 🇺🇸
California Retina Research Consultants, Bakersfield, California, United States
🇺🇸California Retina Consultants CRC, Santa Barbara, California, United States
🇺🇸Southeast Retina Center, PC, Augusta, Georgia, United States
Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201
- Conditions
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02956330
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02952001
- Locations
- 🇺🇸
Valley Eye Physicians and Surgeons, PC, Ayer, Massachusetts, United States
🇮🇳Sri Sankaradeva Nethralaya, Guwahati, Assam, India
🇮🇳JSS Hospital, Mysore, Karnataka, India
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Clearside Biomedical, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02949024
- Locations
- 🇺🇸
Retina Vitreous Associates Medical Group Inc, Mountain View, California, United States
🇺🇸Retina Consultants of Houston, PA, The Woodlands, Texas, United States